{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T20:22:15Z","timestamp":1769286135296,"version":"3.49.0"},"reference-count":105,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["World Neurosurgery"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.wneu.2019.04.032","type":"journal-article","created":{"date-parts":[[2019,9,30]],"date-time":"2019-09-30T03:20:27Z","timestamp":1569813627000},"page":"615-622","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Radiosurgery and Immunotherapy in the Treatment of Brain Metastases"],"prefix":"10.1016","volume":"130","author":[{"given":"Rohan","family":"Ramakrishna","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Formenti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.wneu.2019.04.032_bib1","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/S1470-2045(17)30414-X","article-title":"Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: A single-centre, randomised, controlled, phase 3 trial","volume":"18","author":"Mahajan","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.wneu.2019.04.032_bib2","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/S1470-2045(09)70263-3","article-title":"Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: A randomised controlled trial","volume":"10","author":"Chang","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.wneu.2019.04.032_bib3","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1093\/neuonc\/not114","article-title":"Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: A randomized, double-blind, placebo-controlled trial","volume":"15","author":"Brown","year":"2013","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.wneu.2019.04.032_bib4","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1001\/jama.2016.9839","article-title":"Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: A randomized clinical trial","volume":"316","author":"Brown","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.wneu.2019.04.032_bib5","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1016\/S0140-6736(16)30825-X","volume":"388","author":"Mulvenna","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.wneu.2019.04.032_bib6","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/B978-0-12-811161-1.00012-8","article-title":"Neurocognitive aspects of brain metastasis","volume":"149","author":"Wefel","year":"2018","journal-title":"Handb Clin Neurol"},{"key":"10.1016\/j.wneu.2019.04.032_bib7","first-page":"237","article-title":"Stereotactic radiosurgery using the Leksell Gamma Knife Perfexion unit in the management of patients with 10 or more brain metastases","volume":"117","author":"Grandhi","year":"2012","journal-title":"J\u00a0Neurosurg"},{"key":"10.1016\/j.wneu.2019.04.032_bib8","author":"Bowden"},{"key":"10.1016\/j.wneu.2019.04.032_bib9","first-page":"16","article-title":"Stereotactic radiosurgery for patients with multiple brain metastases: A case-matched study comparing treatment results for patients with 2-9 versus 10 or more tumors","volume":"121","author":"Yamamoto","year":"2014","journal-title":"J\u00a0Neurosurg"},{"key":"10.1016\/j.wneu.2019.04.032_bib10","first-page":"1258","article-title":"A\u00a0case-matched study of stereotactic radiosurgery for patients with multiple brain metastases: Comparing treatment results for 1-4 vs \u22655 tumors: clinical article","volume":"118","author":"Yamamoto","year":"2013","journal-title":"J\u00a0Neurosurg"},{"key":"10.1016\/j.wneu.2019.04.032_bib11","author":"Hughes"},{"key":"10.1016\/j.wneu.2019.04.032_bib12","doi-asserted-by":"crossref","first-page":"15618","DOI":"10.1038\/ncomms15618","article-title":"DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity","volume":"8","author":"Vanpouille-Box","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.wneu.2019.04.032_bib13","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/nrclinonc.2016.211","article-title":"Radiotherapy and immunotherapy: A beneficial liaison?","volume":"14","author":"Weichselbaum","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.wneu.2019.04.032_bib14","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: Integrating immunity's roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.wneu.2019.04.032_bib15","first-page":"3491","article-title":"CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer","volume":"58","author":"Naito","year":"1998","journal-title":"Cancer Res"},{"key":"10.1016\/j.wneu.2019.04.032_bib16","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1126\/science.1129139","article-title":"Type, density, and location of immune cells within human colorectal tumors predict clinical outcome","volume":"313","author":"Galon","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.wneu.2019.04.032_bib17","first-page":"699","article-title":"Prognostic significance of peripheral blood CD8highCD57+ lymphocytes in bladder carcinoma patients after intravesical IL-2","volume":"31","author":"Characiejus","year":"2011","journal-title":"Anticancer Res"},{"key":"10.1016\/j.wneu.2019.04.032_bib18","first-page":"639","article-title":"Prediction of response in cancer immunotherapy","volume":"31","author":"Characiejus","year":"2011","journal-title":"Anticancer Res"},{"key":"10.1016\/j.wneu.2019.04.032_bib19","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nrc3245","article-title":"The immune contexture in human tumours: Impact on clinical outcome","volume":"12","author":"Fridman","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.wneu.2019.04.032_bib20","doi-asserted-by":"crossref","first-page":"R48","DOI":"10.1186\/bcr3148","article-title":"CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer","volume":"14","author":"Liu","year":"2012","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.wneu.2019.04.032_bib21","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1158\/1078-0432.CCR-13-2830","article-title":"Prognostic and predictive values of the immunoscore in patients with rectal cancer","volume":"20","author":"Anitei","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.wneu.2019.04.032_bib22","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/s12916-015-0431-3","article-title":"Relevance of tumor-infiltrating lymphocytes in breast cancer","volume":"13","author":"Dushyanthen","year":"2015","journal-title":"BMC Med"},{"key":"10.1016\/j.wneu.2019.04.032_bib23","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.wneu.2019.04.032_bib24","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1007\/s10147-016-0959-z","article-title":"PD-1\/PD-L1 blockade in cancer treatment: Perspectives and issues","volume":"21","author":"Hamanishi","year":"2016","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.wneu.2019.04.032_bib25","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.radonc.2017.08.009","article-title":"Stereotactic radiosurgery of early melanoma brain metastases after initiation of anti-CTLA-4 treatment is associated with improved intracranial control","volume":"125","author":"An","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.wneu.2019.04.032_bib26","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/pcmr.12538","article-title":"Melanoma central nervous system metastases: Current approaches, challenges, and opportunities","volume":"29","author":"Cohen","year":"2016","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.wneu.2019.04.032_bib27","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1470-2045(16)30053-5","article-title":"Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: Early analysis of a non-randomised, open-label, phase 2 trial","volume":"17","author":"Goldberg","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.wneu.2019.04.032_bib28","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1158\/2326-6066.CIR-18-0067","article-title":"Improved risk-adjusted survival for melanoma brain metastases in the era of checkpoint blockade immunotherapies: Results from a national cohort","volume":"6","author":"Iorgulescu","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.wneu.2019.04.032_bib29","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S1470-2045(18)30139-6","article-title":"Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: A multicentre randomised phase 2 study","volume":"19","author":"Long","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.wneu.2019.04.032_bib30","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.wneu.2019.04.032_bib31","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1084\/jem.20141308","article-title":"Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity","volume":"211","author":"Duan","year":"2014","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.wneu.2019.04.032_bib32","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1084\/jem.184.2.441","article-title":"Loss of a unique tumor antigen by cytotoxic T lymphocyte immunoselection from a 3-methylcholanthrene-induced mouse sarcoma reveals secondary unique and shared antigens","volume":"184","author":"Dudley","year":"1996","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.wneu.2019.04.032_bib33","doi-asserted-by":"crossref","first-page":"6169","DOI":"10.4049\/jimmunol.175.9.6169","article-title":"Tumor progression can occur despite the induction of very high levels of self\/tumor antigen-specific CD8+ T cells in patients with melanoma","volume":"175","author":"Rosenberg","year":"2005","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.wneu.2019.04.032_bib34","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.3389\/fimmu.2017.01850","article-title":"Chimeric antigen receptors T cell therapy in solid tumor: Challenges and clinical applications","volume":"8","author":"Mirzaei","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.wneu.2019.04.032_bib35","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/nature10755","article-title":"Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting","volume":"482","author":"Matsushita","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.wneu.2019.04.032_bib36","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1034\/j.1399-0039.2003.00020.x","article-title":"Total loss of MHC class I in colorectal tumors can be explained by two molecular pathways: Beta2-microglobulin inactivation in MSI-positive tumors and LMP7\/TAP2 downregulation in MSI-negative tumors","volume":"61","author":"Cabrera","year":"2003","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.wneu.2019.04.032_bib37","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nature10803","article-title":"Expression of tumour-specific antigens underlies cancer immunoediting","volume":"482","author":"DuPage","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.wneu.2019.04.032_bib38","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.cell.2014.12.033","article-title":"Molecular and genetic properties of tumors associated with local immune cytolytic activity","volume":"160","author":"Rooney","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.wneu.2019.04.032_bib39","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1126\/science.aaa6204","article-title":"T\u00a0cell exclusion, immune privilege, and the tumor microenvironment","volume":"348","author":"Joyce","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.wneu.2019.04.032_bib40","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/nature25492","article-title":"TGFbeta drives immune evasion in genetically reconstituted colon cancer metastasis","volume":"554","author":"Tauriello","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.wneu.2019.04.032_bib41","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.wneu.2019.04.032_bib42","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/nature08467","article-title":"The DNA-damage response in human biology and disease","volume":"461","author":"Jackson","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.wneu.2019.04.032_bib43","doi-asserted-by":"crossref","first-page":"E4612","DOI":"10.1073\/pnas.1705499114","article-title":"cGAS is essential for cellular senescence","volume":"114","author":"Yang","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.wneu.2019.04.032_bib44","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1084\/jem.20101159","article-title":"Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8\u03b1\u00a0+ dendritic cells","volume":"208","author":"Fuertes","year":"2011","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.wneu.2019.04.032_bib45","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1084\/jem.20101158","article-title":"Type I interferon is selectively required by dendritic cells for immune rejection of tumors","volume":"208","author":"Diamond","year":"2011","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.wneu.2019.04.032_bib46","doi-asserted-by":"crossref","first-page":"e28518","DOI":"10.4161\/onci.28518","article-title":"Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death","volume":"3","author":"Golden","year":"2014","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.wneu.2019.04.032_bib47","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/nm1523","article-title":"Calreticulin exposure dictates the immunogenicity of cancer cell death","volume":"13","author":"Obeid","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.wneu.2019.04.032_bib48","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1038\/nm1622","article-title":"Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy","volume":"13","author":"Apetoh","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.wneu.2019.04.032_bib49","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1038\/nm.2028","article-title":"Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors","volume":"15","author":"Ghiringhelli","year":"2009","journal-title":"Nat Med"},{"key":"10.1016\/j.wneu.2019.04.032_bib50","doi-asserted-by":"crossref","first-page":"5931","DOI":"10.1038\/onc.2016.104","article-title":"Damage-associated molecular patterns in cancer: A double-edged sword","volume":"35","author":"Hernandez","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.wneu.2019.04.032_bib51","doi-asserted-by":"crossref","first-page":"4328","DOI":"10.1158\/0008-5472.CAN-04-0073","article-title":"External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing","volume":"64","author":"Chakraborty","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.wneu.2019.04.032_bib52","doi-asserted-by":"crossref","first-page":"7985","DOI":"10.1158\/0008-5472.CAN-04-1525","article-title":"Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes","volume":"64","author":"Garnett","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.wneu.2019.04.032_bib53","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1084\/jem.20052494","article-title":"Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy","volume":"203","author":"Reits","year":"2006","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.wneu.2019.04.032_bib54","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.semcancer.2008.03.004","article-title":"Macrophage polarization in tumour progression","volume":"18","author":"Sica","year":"2008","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.wneu.2019.04.032_bib55","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1615\/CritRevImmunol.v32.i6.10","article-title":"M1 and M2 Macrophages: Oracles of health and disease","volume":"32","author":"Mills","year":"2012","journal-title":"Crit Rev Immunol"},{"key":"10.1016\/j.wneu.2019.04.032_bib56","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.ijrobp.2003.09.012","article-title":"Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated","volume":"58","author":"Demaria","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.wneu.2019.04.032_bib57","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1158\/1078-0432.728.11.2","article-title":"Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer","volume":"11","author":"Demaria","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.wneu.2019.04.032_bib58","doi-asserted-by":"crossref","first-page":"5379","DOI":"10.1158\/1078-0432.CCR-09-0265","article-title":"Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody","volume":"15","author":"Dewan","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.wneu.2019.04.032_bib59","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1158\/0008-5472.CAN-14-3511","article-title":"TGFbeta is a master regulator of radiation therapy-induced antitumor immunity","volume":"75","author":"Vanpouille-Box","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.wneu.2019.04.032_bib60","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.wneu.2019.04.032_bib61","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.wneu.2019.04.032_bib62","first-page":"674","article-title":"PD-1-targeted immunotherapy: Recent clinical findings","volume":"10","author":"Brahmer","year":"2012","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.wneu.2019.04.032_bib63","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.wneu.2019.04.032_bib64","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.coi.2013.02.009","article-title":"Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment","volume":"25","author":"Gajewski","year":"2013","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.wneu.2019.04.032_bib65","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1305133","article-title":"Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma","volume":"369","author":"Hamid","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.wneu.2019.04.032_bib66","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.wneu.2019.04.032_bib67","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMe1205943","article-title":"Tumor immunotherapy directed at PD-1","volume":"366","author":"Ribas","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.wneu.2019.04.032_bib68","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.wneu.2019.04.032_bib69","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1084\/jem.20100643","article-title":"Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity","volume":"207","author":"Sakuishi","year":"2010","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.wneu.2019.04.032_bib70","doi-asserted-by":"crossref","first-page":"19393","DOI":"10.18632\/oncotarget.5107","article-title":"The anticancer immune response of anti-PD-1\/PD-L1 and the genetic determinants of response to anti-PD-1\/PD-L1 antibodies in cancer patients","volume":"6","author":"Sui","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.wneu.2019.04.032_bib71","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.wneu.2019.04.032_bib72","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"32","author":"Topalian","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.wneu.2019.04.032_bib73","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ijrobp.2012.12.025","article-title":"Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas","volume":"86","author":"Zeng","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.wneu.2019.04.032_bib74","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1158\/2326-6066.CIR-14-0196","article-title":"Stereotactic radiation therapy augments antigen-specific PD-1-mediated antitumor immune responses via cross-presentation of tumor antigen","volume":"3","author":"Sharabi","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.wneu.2019.04.032_bib75","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1158\/2326-6066.CIR-14-0138","article-title":"PD-1 restrains radiotherapy-induced abscopal effect","volume":"3","author":"Park","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.wneu.2019.04.032_bib76","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s40425-016-0156-7","article-title":"Current clinical trials testing the combination of immunotherapy with radiotherapy","volume":"4","author":"Kang","year":"2016","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.wneu.2019.04.032_bib77","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.trecan.2016.05.002","article-title":"Radiotherapy: Changing the game in immunotherapy","volume":"2","author":"Demaria","year":"2016","journal-title":"Trends Cancer"},{"key":"10.1016\/j.wneu.2019.04.032_bib78","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nrc.2018.6","article-title":"Using immunotherapy to boost the abscopal effect","volume":"18","author":"Ngwa","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.wneu.2019.04.032_bib79","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1158\/2326-6066.CIR-14-0069","article-title":"Combining radiation and immunotherapy: A new systemic therapy for solid tumors?","volume":"2","author":"Tang","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.wneu.2019.04.032_bib80","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in Stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.wneu.2019.04.032_bib81","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1056\/NEJMoa1112824","article-title":"Immunologic correlates of the abscopal effect in a patient with melanoma","volume":"366","author":"Postow","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.wneu.2019.04.032_bib82","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1056\/NEJMc1203984","article-title":"Abscopal effect in a patient with melanoma","volume":"366","author":"Hiniker","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.wneu.2019.04.032_bib83","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.ijrobp.2012.03.017","article-title":"The abscopal effect associated with a systemic anti-melanoma immune response","volume":"85","author":"Stamell","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.wneu.2019.04.032_bib84","doi-asserted-by":"crossref","first-page":"e28780","DOI":"10.4161\/onci.28780","article-title":"Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy","volume":"3","author":"Grimaldi","year":"2014","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.wneu.2019.04.032_bib85","doi-asserted-by":"crossref","first-page":"e1046028","DOI":"10.1080\/2162402X.2015.1046028","article-title":"A\u00a0systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab","volume":"4","author":"Chandra","year":"2015","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.wneu.2019.04.032_bib86","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1158\/2326-6066.CIR-13-0115","article-title":"An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer","volume":"1","author":"Golden","year":"2013","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.wneu.2019.04.032_bib87","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S1470-2045(15)00054-6","article-title":"Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: A proof-of-principle trial","volume":"16","author":"Golden","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.wneu.2019.04.032_bib88","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1080\/15384047.2016.1264543","article-title":"Improved survival and complete response rates in patients with advanced melanoma treated with concurrent ipilimumab and radiotherapy versus ipilimumab alone","volume":"18","author":"Koller","year":"2017","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.wneu.2019.04.032_bib89","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1093\/annonc\/mdw417","article-title":"Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF\/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy","volume":"27","author":"Ahmed","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.wneu.2019.04.032_bib90","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s40425-015-0095-8","article-title":"Ipilmumab and cranial radiation in metastatic melanoma patients: A case series and review","volume":"3","author":"Schoenfeld","year":"2015","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.wneu.2019.04.032_bib91","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/cam4.140","article-title":"Ipilimumab and radiation therapy for melanoma brain metastases","volume":"2","author":"Silk","year":"2013","journal-title":"Cancer Med"},{"key":"10.1016\/j.wneu.2019.04.032_bib92","first-page":"227","article-title":"Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival","volume":"117","author":"Knisely","year":"2012","journal-title":"J\u00a0Neurosurg"},{"key":"10.1016\/j.wneu.2019.04.032_bib93","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1097\/COC.0000000000000199","article-title":"Ipilimumab and stereotactic radiosurgery versus stereotactic radiosurgery alone for newly diagnosed melanoma brain metastases","volume":"40","author":"Patel","year":"2017","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.wneu.2019.04.032_bib94","first-page":"1397","article-title":"Combination ipilimumab and radiosurgery for brain metastases: Tumor, edema, and adverse radiation effects","volume":"129","author":"Diao","year":"2018","journal-title":"J\u00a0Neurosurg"},{"key":"10.1016\/j.wneu.2019.04.032_bib95","first-page":"1007","article-title":"The effect of timing of stereotactic radiosurgery treatment of melanoma brain metastases treated with ipilimumab","volume":"127","author":"Cohen-Inbar","year":"2017","journal-title":"J\u00a0Neurosurg"},{"key":"10.1016\/j.wneu.2019.04.032_bib96","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s40425-017-0282-x","article-title":"Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment","volume":"5","author":"Anderson","year":"2017","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.wneu.2019.04.032_bib97","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ejca.2017.07.017","article-title":"Survival of melanoma patients treated with targeted therapy and immunotherapy after systematic upfront control of brain metastases by radiosurgery","volume":"84","author":"Gaudy-Marqueste","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.wneu.2019.04.032_bib98","first-page":"50","article-title":"Melanoma brain metastasis: the impact of stereotactic radiosurgery, BRAF mutational status, and targeted and\/or immune-based therapies on treatment outcome","volume":"129","author":"Kotecha","year":"2018","journal-title":"J\u00a0Neurosurg"},{"key":"10.1016\/j.wneu.2019.04.032_bib99","doi-asserted-by":"crossref","first-page":"e1283461","DOI":"10.1080\/2162402X.2017.1283461","article-title":"Improved time to disease progression in the brain in patients with melanoma brain metastases treated with concurrent delivery of radiosurgery and ipilimumab","volume":"6","author":"Skrepnik","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.wneu.2019.04.032_bib100","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1093\/annonc\/mdv622","article-title":"Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy","volume":"27","author":"Ahmed","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.wneu.2019.04.032_bib101","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1093\/neuonc\/nov093","article-title":"Two heads better than one? Ipilimumab immunotherapy and radiation therapy for melanoma brain metastases","volume":"17","author":"Patel","year":"2015","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.wneu.2019.04.032_bib102","doi-asserted-by":"crossref","first-page":"18945","DOI":"10.18632\/oncotarget.4153","article-title":"Impact of systemic targeted agents on the clinical outcomes of patients with brain metastases","volume":"6","author":"Johnson","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.wneu.2019.04.032_bib103","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.ijrobp.2015.01.004","article-title":"Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: Safety profile and efficacy of combined treatment","volume":"92","author":"Kiess","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.wneu.2019.04.032_bib104","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.adro.2017.07.003","article-title":"Distant intracranial failure in melanoma brain metastases treated with stereotactic radiosurgery in the era of immunotherapy and targeted agents","volume":"2","author":"Acharya","year":"2017","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.wneu.2019.04.032_bib105","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1200\/JCO.2015.60.8448","article-title":"Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center","volume":"33","author":"Horvat","year":"2015","journal-title":"J\u00a0Clin Oncol"}],"container-title":["World Neurosurgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878875019310241?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878875019310241?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T08:34:10Z","timestamp":1761813250000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878875019310241"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":105,"alternative-id":["S1878875019310241"],"URL":"https:\/\/doi.org\/10.1016\/j.wneu.2019.04.032","relation":{},"ISSN":["1878-8750"],"issn-type":[{"value":"1878-8750","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radiosurgery and Immunotherapy in the Treatment of Brain Metastases","name":"articletitle","label":"Article Title"},{"value":"World Neurosurgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.wneu.2019.04.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}